Dual Agonists for Management of Metabolic Dysfunction–Associated Steatohepatitis

Metabolic dysfunction–associated steatohepatitis (MASH) is the most common liver disease worldwide, and its prevalence is increasing rapidly.1 Yet, effective treatments for MASH remain scarce. Obesity plays a central role in MASH. Glucagon-like peptide-1 (GLP-1) receptor agonists are emerging as the most promising antiobesity treatments2 and could…

​   The New England Journal of Medicine: Search Results in Gastroenterology